ProBioGen, Emergent BioSolutions Partner in Vaccine Manufacturing - - BioPharm International

ADVERTISEMENT

ProBioGen, Emergent BioSolutions Partner in Vaccine Manufacturing



ProBioGen has formed an agreement with Emergent BioSolutions for a non-exclusive commercial multiproduct license and option agreement under which Emergent will be granted broad access to ProBioGen’s avian AGE1.CR cell line. Previously, ProBioGen had granted an exclusive license to Emergent for four indications and also conducted process development work for Emergent.  As a result of the new agreement, ProBioGen’s relationship with Emergent is now extended to include additional infectious disease targets, with the option to expand to numerous further indications. The commercial licenses include milestones and royalty payments. Financial details were not disclosed.

Source: ProBioGen

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Harnessing the Power of Modified T Cells to Treat Cancer
October 17, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Industry Stakeholders Tackle the Use of Biological Qualifiers at WHO Naming Session
October 16, 2014
Pfizer Ireland Plant Receives ISPE Award
October 16, 2014
Author Guidelines

Click here